PHT announces availability of eDHP-18 QoL questionnaire on all ePRO collection modalities

PHT Corporation announced today the availability of the electronic version of the DHP-18 (Diabetes Health Profile) Quality of Life (QoL) questionnaire on all of its electronic patient reported outcome (ePRO) collection modalities - smartphone, tablet and Web. PHT is the global pacesetter in PRO and ePRO solutions that maximize the collection of high-quality data from clinical trial patients to improve clinical trial efficiencies.

DHP-18 is an approved and globally-recognized QoL questionnaire used extensively to capture data from diabetes patients. Dr. Keith Meadows, Founder and Director of DHP Research & Consultancy, is the author and copyright owner of the DHP-18. He has more than 25 years' expertise in the psychosocial impact of living with diabetes, health-related quality of life, user involvement and the patient reported experience.

PHT's Science team worked closely with Dr. Meadows to develop the eDHP-18 questionnaire for collecting ePRO data via the PHT smartphone, tablet and Web modalities. When asked why he chose to collaborate with PHT to bring his questionnaire to an electronic format, he explained "Unlike all other ePRO vendors, the PHT Science team provides extensive consulting with every trial, and shares their operational experience at no charge. As a result, the PHT designs help subjects and sites comply with the protocol, and enable trials to improve endpoint data."

He added, "I chose to work with PHT based on the company's breadth of experience not only in providing the premier ePRO system for clinical trials, but also for their scientific expertise in the diabetes indication."

PHT President and CEO Philip Lee said, "Diabetes research has a critical need for ePRO systems that enable researchers to track and analyze key patient measures in real-time. We were the first ePRO vendor to seamlessly integrate glucose readings with patient diary questions and QoL surveys. We're privileged to be working with Dr. Meadows to improve patient safety, compliance and efficiency for vital diabetes research."

Diabetes has rapidly become a global epidemic affecting more than 238 million people. That number is expected to increase to 438 million people by the year 2030. The economic burden of the disease totaled $376 billion in 2010. As such, biopharmaceutical companies and researchers around the world are working to identify new, effective and safe treatments to help this growing patient population.

The use of ePRO systems in clinical research is rapidly increasing as regulatory authorities acknowledge the indisputable improvement of data quality such systems provide, particularly in comparison to paper-based reports completed in unsupervised settings. Many sponsors gain significant return on investment and competitive advantage by collecting symptom, event, and health-related quality of life (HRQoL) data on the same electronic platform. This simplifies and streamlines the entire data collection and management process.